Collaboration’s ambitious objective: the development of a new generation of drugs and non-invasive monitoring tools of the gut microbiome in immuno-oncology.
Professor Alexander Eggermont, CEO of Gustave Roussy, said. We are convinced that Enterome’s unique human microbiome platform and its expertise in understanding the links between the gut microbiome composition and the development of diseases, combined with our world-leading research in immuno-oncology, will allow to deliver novel drugs and diagnostics that could extend the range of personalized treatment options for patients with cancer.”
A dual approach: novel therapeutics and diagnostics for cancer
The collaboration with Gustave Roussy is based around Enterome’s unique metagenomic technology platform that provides a deep understanding of the gut microbiome composition: a key new element in determining how effective cancer immunotherapies are and in identifying personalized ways to boost immune response against tumours. “Still a largely unexplored field, the gut microbiome offers numerous promising avenues for research that may soon lead to a shift to a new treatment paradigm in oncology,” says Enterome CEO Pierre Bélichard.
This perspective is shared by Gustave Roussy’s Tumour and Immunotherapy team which, thanks to progress made in understanding cellular and molecular tumour immunology over the last two decades, has identified new and innovative ways of manipulating the immune response to cancer promising much improved treatments outcome for patients with malignant tumours.
Team director Professor Laurence Zitvogel recently highlighted the crucial role of gut microbiome in eliciting innate and adaptive immune responses beneficial for the host in relation to effective therapies against cancer (chemotherapies, immunotherapy based on immune checkpoint blockers).
Enterome’s understanding of the microbiome space and Gustave Roussy’s extensive development capabilities in the immune-oncology sphere combine to create a complementary partnership that today offers a unique opportunity to co-develop the new generation of cancer drugs.
“This partnership demonstrates the growing interest from a broad range of healthcare players in our gut microbiome-based approach which has the potential to deliver breakthrough treatment solutions for a broad range of diseases” concludes Pierre Bélichard.
Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as inflammatory bowel diseases, cancer, and metabolic diseases.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to meet significant unmet medical needs.
Enterome was established in 2012 in Paris, France, to develop the discoveries made by the INRA metagenomic platform. The company has raised a total of ?17.5m from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and two strategic investors (INRA transfer & Shire).
About Institut Gustave Roussy:
Gustave Roussy is the leading Cancer Centre in Europe. It is a centre where all the skills in cancer care are focused on the patient. It comprises 3,000 professional staff who are engaged in care, research and teaching. – www.gustaveroussy.fr/en – http://www.gustaveroussy.fr/manifesto-cancerinnovation/